First human trial begins for rejuvenation therapy aimed at aging diseases

Life Biosciences has cleared a key regulatory hurdle for the first human test of a rejuvenation therapy built on partial epigenetic reprogramming, a field that has long promised more than it has proven. The company received U.S. Food and Drug Administration clearance for its investigational new drug application for ER-100 on January 28, 2026, setting up the first Phase 1 study in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION.

The trial was designed to test safety first, not aging reversal in the broad sense. It was expected to begin in the first quarter of 2026 and to enroll patients with two optic neuropathies that can cause severe vision loss. Researchers planned to measure tolerability, immune responses and changes in multiple visual outcomes, a practical choice for an early study of a technology that remains far more established in animals than in people.

The scientific premise comes from partial reprogramming, often linked to Yamanaka-factor-based approaches that aim to reset some cellular markers without fully erasing cell identity. That distinction matters. In mouse studies, this type of intervention has been associated with improved health markers, better wound healing, reduced inflammation-related gene expression and extended lifespan in a mouse model of accelerated aging. A 2024 Science Translational Medicine study also reported improved wound healing in aged wild-type mice and reduced expression of proinflammatory cytokines in human primary fibroblasts.

Nature Biotechnology described ER-100 as the first therapy directed at reversing diseases of aging through cellular rejuvenation to reach clinical trials. MIT Technology Review said the move marked the first human test of a rejuvenation method using this technology. Even so, the leap from mice to patients remains enormous. The field still faces major safety questions, including whether reprogramming could disrupt cell identity or create tumor-related problems.

That caution has shaped the tone around the trial. The human study is focused on eye disease, not on broad lifespan extension or sweeping claims about reversing aging. For now, ER-100 is a test of whether a technique that has produced intriguing results in animals can be translated into a controlled clinical setting without crossing the line into harmful biological rewiring. In a field crowded with longevity hype, that distinction may matter as much as the therapy itself.